Literature DB >> 26598277

A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.

Anne-Hilde Muris1, Linda Rolf2, Kelly Broen3, Raymond Hupperts2, Jan Damoiseaux4, Joost Smolders5.   

Abstract

Low circulating 25-hydroxyvitamin D (25(OH)D) levels have been associated with an increased risk of relapses in relapsing remitting multiple sclerosis (RRMS), but an association with disability progression is uncertain. Lower 25(OH)D levels are found in secondary progressive MS (SPMS) when compared to RRMS. We hypothesized that a poor vitamin D status in RRMS is associated with an increased risk of conversion to SPMS. In a retrospective longitudinal study we measured 25(OH)D levels at the start of a 3-year follow-up, and analyzed whether these levels predict the risk of RRMS to SPMS conversion. In 338 RRMS patients, vitamin D status did not predict the 3-year risk of conversion to SPMS (n=51; OR 0.970; p=0.65). However, in diagnostic blood samples of SPMS patients with a relatively short RRMS duration (n=19) 25(OH)D levels were significantly lower (38nmol/L; Q1-Q3: 24-50) than in diagnostic samples of matched RRMS patients with no progression to SPMS ((n=38; 55nmol/L; Q1-Q3: 40-70) (p<0.01). These data indicate an association between a low vitamin D status at the start of RRMS and the early conversion to SPMS. Therefore, time to SPMS conversion is of interest as clinical measure in (follow-up of) clinical vitamin D supplementation studies.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  25-Hydroxyvitamin D; Disability; Relapsing remitting multiple sclerosis; Secondary progressive multiple sclerosis; Vitamin D

Mesh:

Substances:

Year:  2015        PMID: 26598277     DOI: 10.1016/j.jsbmb.2015.11.009

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  6 in total

1.  Vitamin D and MRI measures in progressive multiple sclerosis.

Authors:  Justin R Abbatemarco; Robert J Fox; Hong Li; Daniel Ontaneda
Journal:  Mult Scler Relat Disord       Date:  2019-08-13       Impact factor: 4.339

Review 2.  Illuminating vitamin D effects on B cells--the multiple sclerosis perspective.

Authors:  Linda Rolf; Anne-Hilde Muris; Raymond Hupperts; Jan Damoiseaux
Journal:  Immunology       Date:  2016-02-02       Impact factor: 7.397

3.  Vitamin D Levels and Visual System Measurements in Progressive Multiple Sclerosis: A Cross-sectional Study.

Authors:  Justin R Abbatemarco; Robert J Fox; Hong Li; Robert A Bermel; Daniel Ontaneda
Journal:  Int J MS Care       Date:  2020-04-28

4.  Assessment of Biochemical and Densitometric Markers of Calcium-Phosphate Metabolism in the Groups of Patients with Multiple Sclerosis Selected due to the Serum Level of Vitamin D3.

Authors:  Natalia Niedziela; Krystyna Pierzchała; Jolanta Zalejska-Fiolka; Jacek T Niedziela; Ewa Romuk; Magdalena Torbus-Paluszczak; Monika Adamczyk-Sowa
Journal:  Biomed Res Int       Date:  2018-08-23       Impact factor: 3.411

5.  Sun exposure over the life course and associations with multiple sclerosis.

Authors:  Helen Tremlett; Feng Zhu; Alberto Ascherio; Kassandra L Munger
Journal:  Neurology       Date:  2018-03-07       Impact factor: 9.910

6.  Serum 25 hydroxyvitamin D levels and affecting factors among preconception fertile women.

Authors:  Haiyan Fan; Lingyun Hui; Xiaoting Yan; Wei Hou; E Bai; Li Wang; Xuewen Yu
Journal:  BMC Womens Health       Date:  2020-07-16       Impact factor: 2.809

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.